Phase II
Phase II data showed the triple combination treatment provided 16 months of progression-free survival of patients.
Bavarian Nordic A/S announced that the Data and Safety Monitoring Board confirmed a partial response in one of the first chordoma patients recruited and treated with the combination of BN-Brachyury and radiation treatment at the first evaluation timepoint.
InflaRx reported the top-line results of the international SHINE Phase IIb study, investigating the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in patients suffering from moderate to severe Hidradenitis Suppurativa (HS), a painful and debilitating chronic inflammatory skin disease with limited treatment options.
GENFIT announced the launch of a P2 clinical trial evaluating elafibranor’s activity on liver fat quantity and – most importantly – fat composition in nonalcoholic fatty liver disease (NAFLD) patients.
MD Anderson Phase II study suggests patients with lymphoma subtype may be able to avoid chemotherapy in the future
Minoryx Therapeutics announces that the first patient has been dosed with its lead candidate, leriglitazone, in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.
Arcutis, Inc. announced that it has enrolled the first patient in a Phase 2a clinical trial evaluating ARQ-151 as a potential treatment for atopic dermatitis (AD).
Nivolumab plus ipilimumab meet primary endpoint of MD Anderson NEOSTAR Phase II trial
Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.
Help us identify the leading employers in the life science industry! We want to uncover who leads in key areas like diversity, culture, unique benefits and, of course, who are the 2019 Life Sciences Ideal Employers.
PRESS RELEASES